CRISPR Therapeutics AG (CRSP) Long-Term Investments (2016 - 2025)

CRISPR Therapeutics AG has disclosed Long-Term Investments across 5 years of filings, most recently posting $28.4 million for Q3 2025.

• Long-Term Investments for Q3 2025 came in at $28.4 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $28.4 million (changed N/A YoY), and the FY2023 annual result was $2.0 million, down 96.23% from the prior year.
• Long-Term Investments came in at $28.4 million for Q3 2025 at CRISPR Therapeutics AG, up from $11.2 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $77.1 million in Q3 2022 to a low of $2.0 million in Q4 2023.
• The 4-year median for Long-Term Investments is $9.8 million (2022), against an average of $23.9 million.
• Across the five-year window, Long-Term Investments slumped 96.23% in 2023 and jumped 128.85% in 2024, its largest moves.
• CRISPR Therapeutics AG's Long-Term Investments stood at $53.1 million in 2022, then plunged by 96.23% to $2.0 million in 2023, then surged by 460.8% to $11.2 million in 2024, then jumped by 153.21% to $28.4 million in 2025.
• The last three Long-Term Investments figures came in at $28.4 million (Q3 2025), $11.2 million (Q2 2024), and $2.0 million (Q4 2023), per Business Quant data.